Key result
Implementing apixaban and rivaroxaban measurements is linked to a small increase in thrombolysis use.
Why the study?
Some centers use apixaban/rivaroxaban-calibrated AFXa assays to identify patients with low drug concentrations, motivating evaluation of their clinical implementation.
Does implementation of apixaban and rivaroxaban measurements increase the number of patients receiving thrombolysis in patients with suspected stroke on DOACs?
Cohort
No
Does implementation of apixaban and rivaroxaban measurements increase the number of patients receiving thrombolysis in patients with suspected stroke on DOACs?
Implementing rapid apixaban and rivaroxaban measurements in acute stroke is feasible and safely identifies a small subset of DOAC-treated patients eligible for thrombolysis.
Answers are grounded in this paper and cite their sources.
May aid thrombolysis decisions in DOAC-treated stroke suspects; leaves open whether assay use improves outcomes.
Background: IU/L with low-molecular-weight (LMWH) or unfractionated heparin (UFH) calibrated assays. Some centers also use apixaban/rivaroxaban-calibrated AFXa assays to identify patients with low drug concentrations. Objectives: To prospectively evaluate the first year of implementation of drug-calibrated AFXa assays at our center with 2500 yearly admittances with suspected stroke. Methods: Samples were analyzed on Sysmex CS-5100 instruments with Innovance anti-Xa reagents. Thrombolysis could be considered with drug concentrations <25 μg/L. Patients were registered in an institutionally approved quality register. Outcomes included (1) the number of patients receiving thrombolysis after drug measurement, (2) turn-around time for drug concentration measurements, and (3) sensitivity of LMWH/UFH AFXa to apixaban and rivaroxaban. Results: IU/L, respectively. There were too few rivaroxaban results for regression analysis. Conclusion: Implementation of apixaban and rivaroxaban measurements led to a small increase in the number of patients receiving thrombolysis. Excluding significant concentrations of apixaban or rivaroxaban using LMWH/UFH AFXa may be feasible.
No takes yet. Share an insight, caveat, or question.
Amundsen et al. (2024) conducted a cohort in Suspected stroke. Implementation of drug-calibrated AFXa assays for apixaban and rivaroxaban was evaluated on Number of patients receiving thrombolysis after drug measurement. Implementation of apixaban and rivaroxaban measurements led to a small increase in the number of patients receiving thrombolysis.
Synapse has enriched 10 related papers. Consider them for comparative context: